Tacrolimus and Diabetes in Kidney Transplantation: The Impact of Cyp3a5 Gene Polymorphism

Transplant Proc. 2023 Dec;55(10):2398-2402. doi: 10.1016/j.transproceed.2023.09.029. Epub 2023 Oct 25.

Abstract

Background: To explore the correlation between single nucleotide polymorphisms (SNPs) of CYP3A4 rs2740574 and CYP3A5 rs776746 and post-transplant diabetes mellitus (PTDM) in Chinese renal allograft recipients treated with tacrolimus.

Methods: A total of 244 patients treated with tacrolimus were included in this study, wherein DNA sequencing was detected through fluorescence in situ hybridization, and SNP genotyping was performed.

Results: Among the 244 patients, 44 (18%) developed PTDM. The PTDM group exhibited higher preoperative body mass index and fasting plasma glucose levels, with higher creatinine values one year after surgery. The CYP3A4 rs2740574 genotype was found to be unique in its homozygous AA form. For CYP3A5 rs776746, the genotypes were distributed as follows: 28 (11.5%) cases with AA, 101 (41.4%) cases with AG, and 115 (47.1%) cases with GG, respectively (P = .042). The AA genotype showed a statistically significant difference from both AG and GG genotypes. Furthermore, the A allele of CYP3A5 rs776746 was found to be associated with an increased risk for PTDM development.

Conclusions: The occurrence of tacrolimus-related PTDM is associated with body mass index, fasting plasma glucose levels, and CYP3A5 genotype before renal transplantation. Post-transplant diabetes mellitus is correlated with unfavorable long-term renal graft function, whereas the expression of the CYP3A5 rs776746 gene is linked to an elevated risk of PTDM.

MeSH terms

  • Blood Glucose
  • Cytochrome P-450 CYP3A* / genetics
  • Diabetes Mellitus* / etiology
  • Diabetes Mellitus* / genetics
  • Genotype
  • Humans
  • Immunosuppressive Agents / adverse effects
  • In Situ Hybridization, Fluorescence
  • Kidney Transplantation* / adverse effects
  • Polymorphism, Single Nucleotide
  • Tacrolimus* / adverse effects

Substances

  • Blood Glucose
  • Cytochrome P-450 CYP3A
  • Immunosuppressive Agents
  • Tacrolimus
  • CYP3A5 protein, human